National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

niams.nih.gov

Total trials

99

Active

13

Phase 3

6

Total enrollment

570,534

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 4 of 4 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Doxycycline2
anifrolumab1
Trimethoprim/sulfamethoxazole1
Cephalexin1

Next readouts

  • 2027-01-01
  • 2027-08-01

Top conditions

  • Rheumatoid Arthritis12
  • Systemic Lupus Erythematosus10
  • Dermatomyositis6
  • Ankylosing Spondylitis5
  • Osteoporosis5
  • Polymyositis4
  • Osteoarthritis4
  • Arthritis4

Frequently asked questions about National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

How many clinical trials does National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) have on ClinicalTrials.gov?
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is listed as the lead sponsor on 99 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
How many of National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)'s trials are in Phase 3?
6 of National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)'s trials are in Phase 3, spread across 4 active drug programs.
What therapeutic areas does National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) focus on?
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)'s most-studied conditions on ClinicalTrials.gov are Rheumatoid Arthritis, Systemic Lupus Erythematosus, Dermatomyositis, Ankylosing Spondylitis, Osteoporosis.
When are National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)'s next clinical trial readouts?
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has 2 upcoming primary-completion readouts tracked here; the soonest is “Effects of Treatments on Atopic Dermatitis”, expected around 2027-01-01.